Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:ARDX NASDAQ:MRUS NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$81.64+2.8%$41.04$4.77▼$81.95$6.17B0.56666,365 shs947,592 shsARDXArdelyx$6.38+3.1%$4.73$3.21▼$7.18$1.54B0.684.72 million shs3.04 million shsMRUSMerus$66.10-1.8%$60.73$33.19▼$69.20$5.00B1.09862,245 shs1.10 million shsNUVLNuvalent$76.02-0.1%$78.50$55.53▼$113.51$5.48B1.3533,568 shs511,954 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-0.34%+10.49%+19.32%+1,221.63%+564.13%ARDXArdelyx-0.16%+3.34%+44.63%+53.60%-0.48%MRUSMerus+0.63%+4.42%+2.58%+21.51%+26.92%NUVLNuvalent+1.60%+3.95%-7.09%+1.83%-9.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXAbivax2.7265 of 5 stars3.63.00.00.03.10.80.6ARDXArdelyx4.1399 of 5 stars3.52.00.04.42.12.50.6MRUSMerus2.3295 of 5 stars3.51.00.00.03.42.50.0NUVLNuvalent3.4383 of 5 stars4.51.00.00.03.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.13Buy$92.3313.00% UpsideARDXArdelyx 3.00Buy$11.5081.82% UpsideMRUSMerus 3.08Buy$88.7533.33% UpsideNUVLNuvalent 3.08Buy$118.9157.32% UpsideCurrent Analyst Ratings BreakdownLatest ARDX, ABVX, NUVL, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025MRUSMerusIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$90.008/25/2025MRUSMerusAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$90.008/19/2025NUVLNuvalentPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$112.008/6/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$8.00 ➝ $9.008/6/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/6/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$97.00 ➝ $96.008/5/2025ARDXArdelyxUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$12.008/5/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.008/5/2025ARDXArdelyxWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$13.00 ➝ $14.007/29/2025ABVXAbivaxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $112.007/23/2025ABVXAbivaxLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$74.00(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/AARDXArdelyx$386.15M3.95N/AN/A$0.58 per share10.91MRUSMerus$56.23M89.54N/AN/A$11.13 per share5.98NUVLNuvalentN/AN/AN/AN/A$13.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/AN/AARDXArdelyx-$39.14M-$0.23N/A20.40N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)MRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)NUVLNuvalent-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%11/11/2025 (Estimated)Latest ARDX, ABVX, NUVL, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/A8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 million8/4/2025Q2 2025ARDXArdelyx-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AARDXArdelyxN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.291.251.25ARDXArdelyx1.444.304.03MRUSMerusN/A8.398.39NUVLNuvalentN/A13.5713.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%ARDXArdelyx58.92%MRUSMerus96.14%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AARDXArdelyx4.80%MRUSMerus3.70%NUVLNuvalent10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6175.57 millionN/ANot OptionableARDXArdelyx90240.98 million229.42 millionOptionableMRUSMerus3775.63 million72.84 millionOptionableNUVLNuvalent4072.11 million64.75 millionOptionableARDX, ABVX, NUVL, and MRUS HeadlinesRecent News About These CompaniesNuvalent, Inc. $NUVL Holdings Raised by Affinity Asset Advisors LLCAugust 28 at 9:02 AM | marketbeat.comNuvalent to Participate in the Cantor Global Healthcare Conference 2025August 28 at 6:30 AM | prnewswire.comPrice T Rowe Associates Inc. MD Raises Stock Position in Nuvalent, Inc. $NUVLAugust 28 at 4:52 AM | marketbeat.comNuveen LLC Buys Shares of 83,976 Nuvalent, Inc. $NUVLAugust 28 at 3:36 AM | marketbeat.comT. Rowe Price Investment Management Inc. Makes New $31.97 Million Investment in Nuvalent, Inc. $NUVLAugust 26 at 4:49 AM | marketbeat.comNuvalent, Inc. $NUVL Shares Purchased by American Century Companies Inc.August 26 at 3:50 AM | marketbeat.comNuvalent, Inc. $NUVL Shares Purchased by Wellington Management Group LLPAugust 24, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Sold by Deutsche Bank AGAugust 24, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Sold by Charles Schwab Investment Management Inc.August 24, 2025 | marketbeat.comCandriam S.C.A. Sells 13,966 Shares of Nuvalent, Inc. $NUVLAugust 23, 2025 | marketbeat.comAberdeen Group plc Acquires 19,987 Shares of Nuvalent, Inc. $NUVLAugust 23, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Purchased by Russell Investments Group Ltd.August 22, 2025 | marketbeat.comNuvalent (NASDAQ:NUVL) CEO Sells $2,036,340.00 in StockAugust 21, 2025 | marketbeat.comNuvalent (NASDAQ:NUVL) Now Covered by Piper SandlerAugust 21, 2025 | marketbeat.comInsider Selling: Nuvalent (NASDAQ:NUVL) CEO Sells 27,000 Shares of StockAugust 20, 2025 | insidertrades.comPiper Sandler Initiates Coverage on Nuvalent (NASDAQ:NUVL)August 20, 2025 | americanbankingnews.comPiper Sandler Initiates Coverage of Nuvalent (NUVL) with Overweight RecommendationAugust 19, 2025 | msn.comNuvalent initiated with an Overweight at Piper SandlerAugust 19, 2025 | msn.comVanguard Group Inc. Decreases Holdings in Nuvalent, Inc. $NUVLAugust 19, 2025 | marketbeat.comLord Abbett & CO. LLC Sells 112,621 Shares of Nuvalent, Inc. (NASDAQ:NUVL)August 18, 2025 | marketbeat.comCitigroup Inc. Purchases 112,519 Shares of Nuvalent, Inc. (NASDAQ:NUVL)August 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARDX, ABVX, NUVL, and MRUS Company DescriptionsAbivax NASDAQ:ABVX$81.64 +2.21 (+2.78%) Closing price 04:00 PM EasternExtended Trading$81.52 -0.12 (-0.15%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Ardelyx NASDAQ:ARDX$6.38 +0.19 (+3.07%) Closing price 04:00 PM EasternExtended Trading$6.30 -0.08 (-1.18%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Merus NASDAQ:MRUS$66.10 -1.18 (-1.75%) Closing price 04:00 PM EasternExtended Trading$64.39 -1.71 (-2.59%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Nuvalent NASDAQ:NUVL$76.02 -0.11 (-0.14%) Closing price 04:00 PM EasternExtended Trading$76.03 +0.01 (+0.01%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike at a Crossroads: AI Halo vs. Risks NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access